Stonebrook Private Inc. Acquires 4,106 Shares of DexCom, Inc. (NASDAQ:DXCM)

Stonebrook Private Inc. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 8,370 shares of the medical device company's stock after acquiring an additional 4,106 shares during the period. Stonebrook Private Inc.'s holdings in DexCom were worth $572,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Larson Financial Group LLC lifted its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Nia Impact Advisors LLC lifted its holdings in DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares during the last quarter. Level Four Advisory Services LLC lifted its holdings in DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares during the last quarter. Covestor Ltd lifted its holdings in DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its holdings in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on DXCM shares. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Citigroup reiterated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Stock Performance

NASDAQ DXCM opened at $84.87 on Thursday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.19. The firm has a market capitalization of $33.28 billion, a P/E ratio of 63.34, a price-to-earnings-growth ratio of 1.79 and a beta of 1.44. The firm's fifty day moving average price is $84.01 and its two-hundred day moving average price is $79.93. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the firm earned $0.32 earnings per share. DexCom's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.